GE Healthcare and Takeda Pharmaceutical Company announced an alliance to develop therapeutic drugs in the field of hepatic fibrosis to treat various liver diseases.
GE Healthcare announced on Nov. 11, 2014 an alliance agreement with Takeda Pharmaceutical to research and develop therapeutic drugs to target liver diseases. According to the alliance agreement, GE will provide Takeda with its diagnostic imaging technology to help develop diagnostic technologies and therapeutic drugs for liver diseases.
The collaboration will focus on hepatic fibrosis. The diagnosis of hepatic fibrosis is mostly conducted by a liver biopsy. With this partnership, however, Takeda will be able to use GE’s MR elastography, an MRI used to generate images depicting the elasticity of the body’s internal tissues based on pulses administered externally, to measure the relative stiffness of the liver tissue in a non-invasive manner.
Source: GE Healthcare
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.